Market capitalization | $2.26b |
Enterprise Value | $2.13b |
P/E (TTM) P/E ratio | 20.37 |
EV/FCF (TTM) EV/FCF | 10.03 |
EV/Sales (TTM) EV/Sales | 3.25 |
P/S ratio (TTM) P/S ratio | 3.45 |
P/B ratio (TTM) P/B ratio | 4.20 |
Revenue growth (TTM) Revenue growth | 31.52% |
Revenue (TTM) Revenue | $656.11m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
8 Analysts have issued a Harmony Biosciences Holdings forecast:
8 Analysts have issued a Harmony Biosciences Holdings forecast:
Jun '24 |
+/-
%
|
||
Revenue | 656 656 |
32%
32%
|
|
Gross Profit | 497 497 |
31%
31%
|
|
EBITDA | 203 203 |
18%
18%
|
EBIT (Operating Income) EBIT | 178 178 |
21%
21%
|
Net Profit | 115 115 |
43%
43%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Head office | United States |
CEO | Jeffrey Dayno |
Employees | 246 |
Founded | 2017 |
Website | www.harmonybiosciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.